Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2017 Publisher: Villerton Invest SA, Rue Edward Steichen 14, 2540 Luxembourg
Cefotaxime Sodium for Injection.
| Pharmaceutical Form |
|---|
|
Powder for solution for injection or infusion. Vials containing a white to slightly yellow powder, which when dissolved in Water for Injections forms a straw coloured solution. The intensity of the colour of the solution may vary but this does not indicate differences in potency or safety. |
| Cefotaxime (as cefotaxime sodium) per vial | Diluent to be added | Final concentration of solution |
|---|---|---|
| 500 mg | 2 ml | 500 mg/2.2 ml |
| 1 g | 4 ml | 1 g/4.4 ml |
A quantity of cefotaxime sodium equivalent to 1 g cefotaxime contains approximately 50 mg (2.2 mmol) of sodium.
For excipients see 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Cefotaxime |
Cefotaxime exerts its action by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thereby inhibiting cell wall synthesis. |
| List of Excipients |
|---|
|
None. |
500 mg and 1 g presentations in 10 ml glass vials closed with rubber stoppers and sealed with aluminium caps.
Packaged singly or in cartons of 10, 25 or 50.
Villerton Invest SA, Rue Edward Steichen 14, 2540 Luxembourg
PL 24780/0008
10/10/2011
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
